Company: JUNS
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010990
Chunk: 52

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 8
Chunk 52
---
, we believe, have the knowledge and network
in the South-East Asian market to accelerate steps that is needed to have a product that can have treatment value in the territory.

In March 2025, the Company announced that it had
entered into a partnership with Aquanova AG to develop a series of nutritional products targeting longevity, aging and healthspan. The
first three products, which will focus on the concept of “Beauty from Within”, are slated to hit the market in the third quarter
of 2025 through a Direct-to-Consumer model. The Company will form a wholly-owned subsidiary to focus on the consumer market, and will
market its products on a to-be-developed website targeting the US market, along with social media marketing. Internationally, the Company
is focusing on partners who can market and accelerate sales, with an initial focus on the Asian region.

Financial Position

For the three months
ended March 31, 2025 and March 31, 2024, we have generated no revenues from product sales since inception and incurred net losses of
$1,528,867 and $634,100, respectively, and had negative cash flow from operating activities of $1,063,041 and $65,165, respectively.
As noted in the accompanying condensed consolidated financial statements, as of March 31, 2025, we had a working capital surplus of $1,721,604 and an accumulated
deficit of $27,550,996. There is substantial doubt regarding our ability to continue as a going concern as a result of our
historical recurring losses and negative cash flows from operations as well as our dependence on private equity and financings. See
“Risk Factors—We have a history of operating losses, our management has concluded that factors raise substantial doubt
about our ability to continue as a going concern and our auditor has included an explanatory paragraph relating to our ability to
continue as a going concern in its audit report for the fiscal years ended December 31, 2024 and 2023” in our Form 10-K for fiscal 2024.

Results of Operations

Three Months Ended March 31, 2025 Compared
to the Three Months Ended March 31, 2024

Revenue and Federal Awards

There was no revenue from
product sales during the three months ended March 31, 2025 or 2024 as we are focused on research and development.

Research and Development Expenses

Research and development (“R&D”)
expenses were $466